PHARVARIS NV
Pharvaris NV (PHVS) is a clinical-stage biopharmaceutical company developing small‑molecule therapies for bradykinin‑mediated disorders such as hereditary angioedema (HAE). Investors should know it focuses on oral treatment candidates and early‑to‑mid stage clinical programmes, so value is driven mainly by trial outcomes, regulatory milestones and potential partnerships or licensing deals. The company’s market capitalisation is around $1.54bn, reflecting investor expectations for successful development but also the risks typical of clinical-stage biotech: trial setbacks, regulatory uncertainty and funding needs. Financial runway, data readouts and commercial strategy are key variables to watch. This summary is for educational purposes only and not personal financial advice; investors should assess their own circumstances, consider diversification and be aware that biotech stocks can be volatile and may lose value.
Stock Performance Snapshot
Analyst Rating
Analysts suggest buying PHARVARIS stock, expecting its price to rise to $45.92.
Financial Health
Pharvaris NV is showing positive cash flow and book value, indicating solid financial performance.
View more stocks by downloading the app for FREE
It only takes 60 seconds.
Discover More Opportunities
ACADIA PHARMACEUTICALS INC
ACADIA Pharmaceuticals Inc. is a biopharmaceutical company focused on the development and commercialization of treatments for central nervous system disorders.
ADAPTIVE BIOTECHNOLOGIES CORP
Adaptive Biotechnologies Corporation is a commercial-stage biotechnology company. The Company is focused on harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its immune medicine platform reveals and translates the massive genetics of the adaptive immune system with scale, precision and speed. It applies its platform to partner with biopharmaceutical companies, inform drug development, and develop clinical diagnostics across its two business segments: Minimal Residual Disease (MRD) and Immune Medicine. The MRD business focuses on the use of its sensitive, next-generation sequencing (NGS) assay to measure MRD in patients with hematologic malignancies. Its MRD business is comprised of its clonoSEQ clinical diagnostic test, offered to clinicians. The IM business focuses on the discovery and development of transformative immune-based therapies in the treatment of patients with cancer and autoimmune diseases.
ABCELLERA BIOLOGICS INC
AbCellera Biologics Inc is a biotechnology company that provides technology to discover and develop novel fully human monoclonal antibodies.
Baskets Featuring PHVS
Hematology Stocks | BTK Inhibitor FDA Breakthrough
Following the FDA's approval of Sanofi's Wayrilz, the first BTK inhibitor for a rare blood disorder, a new investment opportunity has emerged. This theme focuses on innovative pharmaceutical companies developing next-generation treatments for rare hematological diseases, a market poised for significant growth.
Published: August 30, 2025
Explore BasketThe Plasma Profit Pipeline
Biopharmaceutical leader CSL reported a 14% surge in annual profit, fueled by its plasma division's success. This highlights a growing investment opportunity in companies involved in the plasma-derived therapies market and the broader bioprocessing supply chain.
Published: August 19, 2025
Explore BasketWhy You’ll Want to Watch This Stock
Oral therapy focus
Developing oral small‑molecule candidates may expand patient convenience and market reach, though clinical success is not guaranteed and trials carry risk.
Data-driven value
Share price sensitivity is often linked to trial readouts and regulatory milestones; positive results can lift sentiment, but outcomes can vary.
Partnership potential
Collaborations or licensing deals could accelerate development and commercial reach, while financing needs and competition remain key considerations.
Why invest with Nemo?
Zero Commission
Trade stocks, ETFs, and more with zero commission. Keep more of your returns.
Trusted & Regulated
Part of Exinity Group 2015, serving over a million customers globally.
6% Interest on Cash
Earn 6% AER on uninvested cash with daily interest payments.
